E-catalog        

Библиогр. в подстроч. примеч.

In the year 2013, India created a stir in the world of pharmaceutical
patents by rejecting patent application of Novartis’ anticancer drug,
Glivec1. This rejection was based on section 3(d) of the Indian patent act2
which precludes evergreening of pharmaceutical patents yet claims to promote
incremental inventions. This report discusses the necessity of a bright
line statute like section 3(d) in a country like India, which has become
pharmacy of the developed world, and yet needs to promote access to cheap
medicines due to low human development index. This necessity has been
examined by studying India’s unique position between the developing and
developed status, infrastructure and human resource at the patent office,
training of patent examiners and the awareness about patent litigations in India.
The report also compares provisions of precluding patent evergreening
by some other countries, with a statute like section 3(d). After giving due